Health & Environmental Research Online (HERO)


Print Feedback Export to File
6416337 
Journal Article 
The safety of medicinal products--current attitudes--better or just new? 
Fletcher, AP 
2001 
0 
Adverse drug reactions and toxicological reviews
ISSN: 0964-198X 
20 
4 
181-184 
English 
11770169 
The mumps, measles and rubella (MMR) vaccine debate continues, cerivastatin (Baycol) is withdrawn from the market (and all other statins come under suspicion), blood and blood products containing the infective agent for hepatitis C are found defective under the Consumer Protection Act (1987) and the media stirs up alarm and despondency. In the United Kingdom (UK) the Medicines Act went on the statute book in 1968 and was fully implemented in 1972. A new era beckoned and we believed that the safety of medicinal products was assured. The Committee on Safety of Medicines (CSM) and its sub-committees and the Medicines Commission would provide advice from the cutting edge of medical science, the 'Yellow Card' scheme would give warning signals of adverse reactions and drug disasters would be a thing of the past. As we all know, that was an unfulfilled dream and nothing seems to have changed. 
; Drugs; Side effects; Legislation; Government regulations; Public health; Blood; Vaccines; Pharmaceuticals; Reviews/